ringerlösung fresenius
fresenius kabi deutschland gmbh (3003660) - calciumchlorid-dihydrat; kaliumchlorid; natriumchlorid - infusionslösung - calciumchlorid-dihydrat (00059) 0,33 gramm; kaliumchlorid (00163) 0,3 gramm; natriumchlorid (00211) 8,6 gramm
dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - mittel gegen dermatitis, ausgenommen corticosteroide - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
alphanine 1000
grifols deutschland gmbh (8092102) - blutgerinnungsfaktor ix ((gefriergetrocknetes produkt gemäß ph.eur.: siehe ask-nr. 03800-8)) - trockensubstanz und lösungsmittel - teil 1 - trockensubstanz; blutgerinnungsfaktor ix ((gefriergetrocknetes produkt gemäß ph.eur.: siehe ask-nr. 03800-8)) (06224) 1000 internationale einheit
alphanine 500
grifols deutschland gmbh (8092102) - blutgerinnungsfaktor ix ((gefriergetrocknetes produkt gemäß ph.eur.: siehe ask-nr. 03800-8)) - trockensubstanz und lösungsmittel - teil 1 - trockensubstanz; blutgerinnungsfaktor ix ((gefriergetrocknetes produkt gemäß ph.eur.: siehe ask-nr. 03800-8)) (06224) 500 internationale einheit
dorzocomp-vision sine 20 mg/ml + 5 mg/ml augentropfen, lösung im einzeldosisbehältnis
omnivision gmbh - dorzolamid hydrochlorid; timololmaleat -
dorzolamid + timolol pharma stulln 20 mg/ml + 5 mg/ml augentropfen, lösung
pharma stulln gmbh - dorzolamid hydrochlorid; timololmaleat -
dorzolamid + timolol stulln sine 20 mg/ml + 5 mg/ml augentropfen, lösung im einzeldosisbehältnis
pharma stulln gmbh - dorzolamid hydrochlorid; timololmaleat -
dorzolamid + timolol stulln 20 mg/ml + 5 mg/ml augentropfen, lösung
pharma stulln gmbh - dorzolamid hydrochlorid; timololmaleat -
palladon injekt 100 mg
mundipharma gesellschaft mit beschränkter haftung - geschäftsanschrift - (3083021) - hydromorphonhydrochlorid - injektionslösung - teil 1 - injektionslösung; hydromorphonhydrochlorid (00108) 100 milligramm
azur compositum
aristo pharma gmbh (3082323) - codeinphosphat-hemihydrat; coffein; paracetamol - zäpfchen - teil 1 - zäpfchen; codeinphosphat-hemihydrat (00087) 40 milligramm; coffein (00088) 50 milligramm; paracetamol (01212) 600 milligramm